In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Editas partners with Juno to create new CAR/TCR therapies

Executive Summary

Editas Medicine Inc. and Juno Therapeutics Inc. joined forces in an exclusive collaboration that sees the partners combining Editas’ disruptive genome editing technologies with Juno’s chimeric antigen receptor (CAR) and T-cell receptor (TCR) immunotherapies to work on three new research programs in cancer.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register